Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Henry Ford Hospital
mi
from
Detroit, MI
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
The University of Texas Health Science Center at Houston
mi
from
Houston, TX
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
The University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated:  5/9/2013
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery
Status: Enrolling
Updated: 5/9/2013
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases
Status: Enrolling
Updated:  6/3/2013
Roger Williams Medical Center
mi
from
Providence, RI
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases
Status: Enrolling
Updated: 6/3/2013
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated:  6/17/2013
Norton Hospital
mi
from
Louisville, KY
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated: 6/17/2013
Norton Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated:  6/17/2013
University of Louisville Hospital
mi
from
Louisville, KY
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer
Status: Enrolling
Updated: 6/17/2013
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Phase I Trial of Gemcitabine With TheraSphere® (Yttrium-90) in Patients With Hepatic Tumors of Pancreatobiliary Origin
Status: Enrolling
Updated:  9/10/2013
Emroy University
mi
from
Atlanta, GA
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Phase I Trial of Gemcitabine With TheraSphere® (Yttrium-90) in Patients With Hepatic Tumors of Pancreatobiliary Origin
Status: Enrolling
Updated: 9/10/2013
Emroy University
mi
from
Atlanta, GA
Click here to add this to my saved trials
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma
Status: Enrolling
Updated:  9/30/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma
Status: Enrolling
Updated: 9/30/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated:  10/16/2013
Massachusetts General Hospital Mass General Hospital
mi
from
Boston, MA
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated: 10/16/2013
Massachusetts General Hospital Mass General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated:  10/16/2013
Research Medical Center Onc Dept
mi
from
Kansas City, MO
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated: 10/16/2013
Research Medical Center Onc Dept
mi
from
Kansas City, MO
Click here to add this to my saved trials
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Status: Enrolling
Updated:  10/25/2013
Massachusetts General Hospital
mi
from
Boston, MA
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT
Status: Enrolling
Updated: 10/25/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Status: Enrolling
Updated:  11/19/2013
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Status: Enrolling
Updated: 11/19/2013
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
Click here to add this to my saved trials
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma.
Status: Enrolling
Updated:  1/12/2014
Stanford Genome Technology Center
mi
from
Stanford, CA
Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.
Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma.
Status: Enrolling
Updated: 1/12/2014
Stanford Genome Technology Center
mi
from
Stanford, CA
Click here to add this to my saved trials
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
Trans-Arterial Chemo-Embolization (TACE) vs TACE Plus Stereotactic Body Radio Therapy (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/24/2014
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
Trans-Arterial Chemo-Embolization (TACE) vs TACE Plus Stereotactic Body Radio Therapy (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/24/2014
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C
Status: Enrolling
Updated:  3/19/2014
Massachusetts General Hospital
mi
from
Boston, MA
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C
Status: Enrolling
Updated: 3/19/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C
Status: Enrolling
Updated:  3/19/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C
Status: Enrolling
Updated: 3/19/2014
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C
Status: Enrolling
Updated:  3/19/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C
Status: Enrolling
Updated: 3/19/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  5/19/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 5/19/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated:  5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated: 5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)
A Pilot Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary SPECT
Status: Enrolling
Updated:  7/10/2014
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)
A Pilot Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary SPECT
Status: Enrolling
Updated: 7/10/2014
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Status: Enrolling
Updated:  10/14/2014
The Center for Cancer Prevention & Treatment at St. Joseph Hospital of Orange
mi
from
Orange, CA
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Status: Enrolling
Updated: 10/14/2014
The Center for Cancer Prevention & Treatment at St. Joseph Hospital of Orange
mi
from
Orange, CA
Click here to add this to my saved trials
MR-Guided Laser Ablation of Hepatic Tumors
Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors
Status: Enrolling
Updated:  10/24/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
MR-Guided Laser Ablation of Hepatic Tumors
Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors
Status: Enrolling
Updated: 10/24/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Graham Hospital
mi
from
Canton, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Canton
mi
from
Canton, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Canton
mi
from
Canton, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Memorial Hospital
mi
from
Carthage, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Carthage
mi
from
Carthage, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Eureka Community Hospital
mi
from
Eureka, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Mason District Hospital
mi
from
Havana, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Havana
mi
from
Havana, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Havana
mi
from
Havana, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Kewanee Clinic
mi
from
Kewanee, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
McDonough District Hospital
mi
from
Macomb, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Macomb
mi
from
Macomb, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
mi
from
Moline, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
mi
from
Moline, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Monmouth
mi
from
Monmouth, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Monmouth
mi
from
Monmouth, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
OSF Holy Family Medical Center
mi
from
Monmouth, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
OSF Holy Family Medical Center
mi
from
Monmouth, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Community Cancer Center
mi
from
Normal, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Community Cancer Center
mi
from
Normal, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Illinois CancerCare - Pekin
mi
from
Pekin, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Illinois CancerCare - Pekin
mi
from
Pekin, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
Proctor Hospital
mi
from
Peoria, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/3/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/3/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials